SYRE Spyre Therapeutics Inc

$SYRE this thing is so strong. No position for me but kinda looks like there are some buyers interested and negotiating a BO

Spyre Therapeutics shares rebounded as investors looked past dilution concerns following the company’s recently completed $350 million public offering. The stock is trading below the $85 offering price, attracting buyers who view the discount as an attractive entry point after the recent selling pressure. Separately, Jefferies highlighted Syros Pharmaceuticals as one of its top small- and mid-cap biotech picks for 2027, citing data presented at United European Gastroenterology Week 2026. The firm sees positive implications from real-world findings on combination therapy for Crohn’s disease and ulcerative colitis, although the available disclosure remains limited. Its investment thesis centers on long-acting combination treatments and co-formulations that could deliver differentiated dosing and efficacy in inflammatory bowel disease. A modest recovery in the broader market, supported by lower oil prices and easing geopolitical tensions. $SYRE

$SYRE This company has actual catalysts in Q4 so the share price might hold up reasonably well despite the offering. Let’s see what happens

$SYRE: Spyre Therapeutics priced a public offering of 4.12 million shares at $85 per share, targeting approximately $350 million in gross proceeds.

$SYRE Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock "today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million"

Spyre Therapeutics launched an underwritten public offering of its common stock on Nasdaq. Underwriters will have a 30-day option to purchase up to 15% of the shares offered under the same terms. Jefferies, TD Cowen, Leerink Partners and Stifel are serving as joint book-running managers, with LifeSci Capital acting as passive bookrunner. Spyre plans to use the net proceeds to advance its Gastroenterology, Rheumatology and Dermatology programs, including preclinical studies, clinical trials, manufacturing and Phase 3 preparation. The company also plans to advance SPY072 into late-stage development for hidradenitis suppurativa. Remaining proceeds will support R&D, working capital and general corporate purposes. The offering remains subject to market conditions, with no assurance regarding its completion, size or final terms. Spyre focuses on long-acting antibody programs targeting a4p7, TL1A, IL-23 and IL-17A/F. $SYRE

$SYRE Had a feeling the IL-23 monotherapy readout would be priced in. Even though it’s expected data it’s great all their monoclonals are at or above expected baseline efficacy. This company is locked in for its combo readouts next year. Bold prediction: SKYLINE IL-23/TL1A combo will exceed the efficacy seen with IL-23/TNF in historical IBD trials.